Amarin Corp Plc (AMRN)

[dogn]

Amarin was paid $15 million up front in 2015 by Eddingpharm upon the signing of a partnership for China with Amarin

Also same doc. pg. 383 (Financial Info), lists "Prepayments for exclusive rights on new drugs" for Vascepa in each of 2017-2021 totaling 716M RMB ($106.25M USD). I don't know if these are the milestone payments noted in the agreement below, if they've actually been paid or are deferred? Regardless, it seems Amarin is pretty committed to keep moving forward with Edding. Agreement below also notes termination terms.



Agreement with Amarin is on doc. p. 259-60:

Vascepa
In February 2015, we entered into a development, commercialization and supply agreement for Vascepa with Amarin. Under the agreement, we obtained an exclusive, payment-bearing license (with the right to sublicense under certain circumstances) under certain patents and know-how of Amarin to develop and commercialize Vascepa in China, Hong Kong, Macau and Taiwan in the field of all human pharmaceutical uses, among others.In accordance with the agreement, we and Amarin established a joint development committee with equal representation from each party to coordinate, oversee and make decisions in relation to the development of Vascepa in the licensed territories. We are obligated to use commercially reasonable efforts to develop and commercialize Vascepa according to the relevant development and commercialization plans. In particular, we are responsible for carrying out research and development activities in the licensed territories at our own cost, including conducting bridging studies, clinical studies and post-regulatory approval studies as well as preparing relevant regulatory approval filings.
We are responsible for the preparation of all the regulatory materials for obtaining the relevant approvals. Amarin is obligated to use commercially reasonable efforts to manufacture and supply all quantities of the finished products or bulk products for clinical and commercial use in the licensed territories. Under the terms of the agreement, we made an upfront payment to Amarin of US$15.0 million (equivalent to RMB97.6 million), and we may be required to pay further milestone payments to Amarin of up to an aggregate of US$154.0 million (equivalent to RMB1,002.5 million) if certain development and sales milestones are achieved. In addition, we will pay Amarin royalties at tiered double-digit percentage rates in the range of low- to mid-teens on the net sales of Vascepa, until the later of (i) the date on which Vascepa is no longer covered by a valid claim of a relevant patent, or (ii) the twelfth anniversary of the first commercial sale of Vascepa in China. Our agreement with Amarin will remain in effect until the expiration of the royalty term and may be terminated early by either party for the other party’s uncured material breach or as a result of bankruptcy. In addition, we can terminate the agreement immediately following the third anniversary of the first commercial sale of Vascepa in China.